Product Showcase and Live Clinical Case Transmissions Set
SUNRISE, Fla., Sept. 16 /PRNewswire-FirstCall/ -- Bioheart, Inc., a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced the following presentations at upcoming fall scientific meetings:
The meeting runs September 21-24, 2008 in Toronto, Ontario, Canada.
“We are continuing to make progress in both our clinical program and our efforts to launch complementary product offerings. We are also pleased that industry luminaries like Drs. Schatz and Sherman are involved in the MARVEL Trial,” said Howard J. Leonhardt, Chairman and Chief Executive Officer of Bioheart, Inc.
ABOUT BIOHEART 3370(TM) HEART FAILURE MONITOR AND POCKET ECG
The Bioheart 3370(TM) Heart Failure Monitor, which is manufactured by Tunstall Healthcare and distributed by Bioheart on a non-exclusive basis, is authorized for commercial sale in the U.S. and all countries recognizing CE Mark designation. The PocketECG, manufactured by Medicalgorithmics, Ltd., Poland, recently received CE mark approval for marketing throughout Europe and U.S. 510(k) approval is being sought in the United States. Bioheart has signed a non-binding letter of intent to acquire Medicalgorithmics
ABOUT MYOCELL(R) CLINICAL CELL THERAPY
MyoCell(R) clinical cell therapy, developed by Bioheart, Inc., is currently being studied as an investigational product in Europe and the U.S. MyoCell(R) clinical cell therapy is intended to be used to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack. The procedure involves a physician removing a small amount of muscle obtained from the patient’s thigh. From this muscle specimen, autologous myoblasts (muscle stem cells) are then isolated, grown using Bioheart’s proprietary cell-culturing process, and injected directly into the scar tissue of the patient’s heart. The myoblast cells are delivered via an endoventricular needle-injection catheter during a minimally invasive procedure performed by an interventional cardiologist or vascular surgeon. The myoblast-based muscle formation in the newly populated regions of scar tissue are intended to improve cardiac function by helping the heart muscle beat more efficiently. To date, more than 365 patients have been included in myoblast transplantation for treating advanced heart failure in clinical trials worldwide.
ABOUT BIOHEART, INC.
Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient’s quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company’s pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit www.bioheartinc.com.
CONTACT: Marty Schildhouse, +1-305-606-3577, mschildh@aol.com, or Rob
Murphy, +1-908-276-0777, rmurphy@storchmurphy.com, both of The Storch
Murphy Group
Web site: http://www.bioheartinc.com/
